What does this research mean for the field?

Prior deep vein thrombosis, lower baseline hemoglobin, and severe baseline systolic pulmonary artery pressure (≥60 mmHg) are independent predictors of 1-year residual pulmonary hypertension in patients treated with percutaneous therapy for pulmonary embolism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to identify clinical predictors of residual pulmonary hypertension 1 year after pulmonary embolism treatment by catheter-directed therapies.

February 22, 2026Open Access

Clinical predictors of residual pulmonary hypertension at 1-year follow-up after pulmonary embolism treated by catheter-directed therapies, a sub-analysis of the USAT IH-PE registry

Key Result

Prior DVT (OR 5.33), baseline hemoglobin (OR 0.76 per 1g/dl), and sPAP ≥60 mmHg at presentation (OR 7.65) predict 1-year residual pulmonary hypertension after PE treatment.

Key Points

This research aims to identify clinical predictors of residual pulmonary hypertension 1 year after pulmonary embolism treatment by catheter-directed therapies.
Analyzed data from the USAT IH-PE registry including 135 patients with pulmonary embolism treated with percutaneous therapy.
Primary endpoint assessed was residual pulmonary hypertension defined by systolic pulmonary artery pressure ≥ 40 mmHg at approximately 1 year.
Used univariable and multivariable logistic regression analyses to determine predictors of residual pulmonary hypertension.
11.1% of patients exhibited residual pulmonary hypertension at 1-year follow-up.
Independent predictors included prior deep-vein thrombosis, baseline hemoglobin level, and initial systolic pulmonary artery pressure ≥ 60 mmHg.
Higher baseline pulmonary pressure significantly increased risk of 1-year residual hypertension.

Structured PICO

Population

135 patients with pulmonary embolism (PE) undergoing percutaneous treatment (catheter-directed therapies), from the USAT IH-PE Registry.

Intervention

Percutaneous therapy / transcatheter intervention for pulmonary embolism

Outcome

Residual pulmonary hypertension (PH), defined as systolic pulmonary artery pressure (sPAP) ≥ 40 mmHg at ≈1 yearsurrogate

Severe baseline pulmonary hypertension and prior deep vein thrombosis are strong independent predictors of residual pulmonary hypertension at 1 year in patients treated with percutaneous therapy for pulmonary embolism.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Introduction Residual pulmonary hypertension (PH) after pulmonary embolism (PE) impairs functional recovery and survival. Among patients treated with percutaneous therapy, determinants of late PH are insufficiently characterized. We aimed to identify 1-year predictors of PH in a cohort treated with transcatheter intervention. Methods and Results Out of the 275 PE patients undergoing percutaneous treatment enrolled in the USAT IH-PE Registry, 135 were included. The primary endpoint was residual PH, defined as systolic pulmonary artery pressure (sPAP) 40 ≥ mmHg at ≈1 year, which occurred in 15/135 (11.1%). On univariable analyses, baseline sPAP ≥ 60 mmHg (30.8% vs 8.2%; p=0.014), prior deep-vein thrombosis (25.0% vs 8.2%; p=0.018), prior PE (30.0% vs 9.6%; p=0.048), and need for non-invasive ventilation (26.7% vs 9.5%; p=0.049) were associated with the endpoint; thrombus location across bilateral principal, bilateral lobar, and unilateral principal was related (p=0.017). At the multivariable logistic regression analysis, three variables emerged as independent predictors of residual pulmonary hypertension at 1 year follow-up: a prior history of DVT (OR, 5.33; 95% CI, 1.05–26.9; p=0.043), baseline hemoglobin level at admission (OR for 1g/dl increase, 0.76; 95% CI, 0.59–0.98; p=0.032) and sPAP ≥ 60 mmHg at presentation (OR, 7.65; 95% CI, 1.50–39.1; p=0.014). Conclusions In PE patients after percutaneous therapy, severe baseline PH and prior venous thromboembolism identify a high risk of 1-year residual PH.